The company specializes in small-molecule treatments targeting autoimmune, metabolic, and oncological conditions. Despite maintaining a pipeline of three developed drugs and six candidates, HJ Science has yet to secure commercial approval for any of its products. This lack of revenue-generating assets leaves the firm vulnerable in an industry dominated by global players with deeper pockets and more established portfolios.

Management acknowledged in exchange filings that its pipeline faces direct competition from entrenched rivals whose products often hold significant advantages. While the broader Chinese biopharma sector continues to draw interest through high-profile licensing deals and rapid innovation cycles, HJ Science struggles to prove it can survive the transition from research to market. Investors remain cautious as the company contends with these competitive pressures and the high cost of drug development.